Markets:

Overview

News

Currencies

International

Treasuries

Zoetis (NY:ZTS)

126.65 +1.01 (+0.80%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

ZTS Q4 Deep Dive: Product Innovation and Competitive Pressures Shape Outlook

Today 0:35 EST

Animal health company Zoetis (NYSE:ZTS) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue...

Via StockStory

Analysts Question Zoetis' Pathway To Growth As Key Segments Slide ↗

February 12, 2026

Animal health firm Zoetis Inc. (NYSE: ZTS) reports Q4 2025 earnings, with adjusted EPS of $1.48 beating consensus of $1.40.

Via Benzinga

Zoetis (ZTS) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Zoetis (ZTS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Bonds Earnings

Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market

February 12, 2026

Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,...

Via Finterra

Topics Artificial Intelligence Earnings Economy

Zoetis Inc. (NYSE:ZTS) Reports Q4 Earnings Beat and Steady 2026 Guidance ↗

February 12, 2026

Via Chartmill

Topics Earnings

Zoetis Inc. (NYSE:ZTS): A Dependable Dividend Stock Built on Financial Strength ↗

January 31, 2026

Via Chartmill

Zoetis’s (NYSE:ZTS) Q4 CY2025 Sales Top Estimates

February 12, 2026

Animal health company Zoetis (NYSE:ZTS) announced better-than-expected revenue in Q4 CY2025, with sales up 3% year on year to $2.39 billion. The company expects the full year’s revenue to be around...

Via StockStory

Zoetis Reports Fourth Quarter and Full Year 2025 Results

February 12, 2026

From Zoetis Inc.

Via Business Wire

Zoetis (ZTS) Reports Q4: Everything You Need To Know Ahead Of Earnings

February 10, 2026

Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Zoetis Inc (NYSE:ZTS) Passes Key Quality Investing Screen ↗

January 24, 2026

Via Chartmill

ZOETIS INC (NYSE:ZTS) Stands Out as a Durable Dividend Stock for Income Investors ↗

January 06, 2026

Via Chartmill

Should You Buy Zoetis Before Feb. 12? ↗

February 09, 2026

After walking back guidance last quarter, could this animal health company reveal surprises come earnings day?

Via The Motley Fool

Topics Earnings

Zoetis Declares Second Quarter 2026 Dividend

February 05, 2026

From Zoetis Inc.

Via Business Wire

USDA Unveils $100 Million 'Grand Challenge' to Thwart Flesh-Eating Screwworm as Threat Reaches U.S. Border

February 05, 2026

In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New...

Via MarketMinute

Topics Death Economy

1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

February 01, 2026

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

2 Healthcare Stocks Poised for a Comeback in 2026 ↗

January 22, 2026

Don't wait too long to press the buy button on these comeback stories.

Via The Motley Fool

This Could Be One of the Best Healthcare Stock Buying Opportunities I've Seen in Years ↗

January 22, 2026

Trading at a once-in-a-decade low valuation, this leading animal healthcare stock deserves a long look from investors.

Via The Motley Fool

Q3 Earnings Roundup: Zoetis (NYSE:ZTS) And The Rest Of The Branded Pharmaceuticals Segment

January 20, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 of Wall Street’s Favorite Stocks with Solid Fundamentals and 1 Facing Challenges

January 18, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Profitable Stock with Solid Fundamentals and 2 We Brush Off

January 15, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

Topics Bankruptcy

Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy

January 08, 2026

LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal...

Via MarketMinute

Topics Earnings Economy

The Paws-Solidation Era: How 2025 Became the Record-Breaking Year for Pet Care M&A

January 07, 2026

As 2025 comes to a close, the financial landscape of the pet care industry has been fundamentally reshaped by a tidal wave of mergers and acquisitions. What began as a post-pandemic stabilization...

Via MarketMinute

Topics Artificial Intelligence Economy

2 Safe-and-Steady Stocks with Competitive Advantages and 1 We Turn Down

January 06, 2026

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

2 Beaten-Down Stocks That Could Bounce Back in 2026 ↗

December 31, 2025

It's not time to give up on these companies yet.

Via The Motley Fool

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

December 30, 2025

From Zoetis Inc.

Via Business Wire

Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025

December 24, 2025

As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D...

Via MarketMinute

Topics Bonds Earnings World Trade

Regulatory Roadblock: ImmuCell Pivots to Core Growth After FDA Rejects Mastitis Treatment

December 24, 2025

In a significant strategic shift that marks the end of a multi-year regulatory odyssey, ImmuCell Corporation (Nasdaq: ICCC) announced late yesterday, December 23, 2025, that it has received another...

Via MarketMinute

Got $5,000? These 3 Growth Stocks Are Trading Near Their Lows. ↗

December 19, 2025

Don't overlook these potential bargain buys -- they may not stay down for long.

Via The Motley Fool

Topics Death

Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Zoetis Inc.

Via Business Wire

These 2 Healthcare Stocks Just Declared Dividend Raises ↗

December 17, 2025

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.